Shots:
- Arrowhead has granted Novartis exclusive global rights to develop, manufacture, & commercialize ARO-SNCA, which leverages the TRiM platform for SC dosing & targeted gene delivery to treat synucleinopathies, incl. Parkinson’s disease
- As per the deal, Arrowhead will receive $200M upfront & ~$2B in development, regulatory, and sales milestones, with tiered royalties on sales up to the low double digits; closing expected in H2’25
- Under the collaboration, Novartis may select additional TRiM-based targets, while Arrowhead handles preclinical work for CTA filings across all licensed programs before Novartis assumes full responsibility for development, manufacturing, medical affairs, & commercialization
Ref: Arrowhead | Image: Arrowhead & Novartis | Press Release
Related News:- IDEAYA Biosciences Partners with Servier to Develop and Commercialize Darovasertib for Uveal Melanoma (UM)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
